A randomised, placebo controlled clinical trial of the aldose reductase inhibitor CT-112 as management of corneal epithelial disorders in diabetic patients

British Journal of Ophthalmology

Volumn 89, Issue 3, 2005, Pages 266-268

  Nakahara, M ^a   Miyata, K ^a   Otani, S ^a   Miyai, T ^a   Nejima, R ^a   Yamagami, S ^b   Amano, Shiro ^b,c  

^a Miyata Eye Hospital   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDOSE REDUCTASE INHIBITOR; EPALRESTAT; FLUORESCEIN; PLACEBO; RISARESTAT;

ADULT; ARTICLE; BASEMENT MEMBRANE; CELL MEMBRANE PERMEABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA DISEASE; CORNEA EPITHELIUM; CORNEA SENSIBILITY; DIABETES MELLITUS; DIABETIC KERATOPATHY; DRUG EFFICACY; ENZYME INHIBITION; EPITHELIUM CELL; FEMALE; FLUOROPHOTOMETRY; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

AGED; ALDEHYDE REDUCTASE; CORNEAL ULCER; DIABETES MELLITUS; DOUBLE-BLIND METHOD; EPITHELIUM, CORNEAL; FLUORESCEIN; FLUOROPHOTOMETRY; HUMANS; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PERMEABILITY; PROSPECTIVE STUDIES; SENSORY THRESHOLDS; STATISTICS, NONPARAMETRIC; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 14744281815     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2004.049841     Document Type: Article

References (25)

1. Schultz RO, Van Horn DL, Peters MA, et al. Diabetic keratopathy. Trans Am Ophthalmol Soc 1981;79:180-9.
2. Perry HD, Foulks GN, Thoft RA, et al. Corneal complications after closed vitrectomy through the pars plana. Arch Ophthalmol 1978;96:1401-3.
3. Brightbill FS, Myers FL, Bresnick GH. Postvitrectomy keratopathy. Am J Ophthalmol 1978;85:651-5.
4. Foulks GN, Thoft RA, Perry HD, et al. Factors related to corneal epithelial complications after closed vitrectomy in diabetics. Arch Ophthalmol 1979;97:1076-8.
5. Chung H, Tolentino FI, Cajita VN, et al. Reevaluation of corneal complications after closed vitrectomy. Arch Ophthalmol 1988;106:916-9.
6. Kinoshita JH, Fukushi S, Kador P, et al. Aldose reductase in diabetic complications of the eye. Metabolism 1979;28:462-9.
7. Cogan DG, Kinoshita JH, Kador PF, et al. Aldose reductase and complications of diabetes. Ann Intern Med 1984;101:82-91.
8. Akagi Y, Yajima Y, Kador PF, et al. Localization of aldose reductase in the human eye. Diabetes 1984;33:562-6.
9. Koji Y, Usui T, Oshika T, et al. Advanced glycation end products in diabetic corneas. Invest Ophthalmol Vis Sci 2000;41:362-8.
10. Fujishima H, Shimazaki J, Yagi Y, et al. Improvement of corneal sensation and tear dynamics in diabetic patients by oral aldose reductase inhibitor, ONO-2235: a preliminary study. Cornea 1996;15:368-72.
11. Fujishima H, Tsubota K. Improvement of corneal fluorescein staining in post cataract surgery of diabetic patients by an oral aldose reductase inhibitor, ONO-2235. Br J Ophthalmol 2002;86:860-3.
12. Hosotani H, Ohashi Y, Yamada M, et al. Reversal of abnormal corneal epithelial cell morphologic characteristics and reduced corneal sensitivity in diabetic patients by aldose reductase inhibitor, CT-112. Am J Ophthalmol 1995;119:288-94.
13. Yokoi N, Niiya A, Komuro A, et al. Effects of aldose reductase inhibitor CT-112 on the corneal epithelial barrier of galactose-fed rats. Curr Eye Res 1997:595-9.
14. Miyata K, Amano S, Sawa M, et al. A novel grading method for superficial punctate keratopathy magnitude and its correlation with corneal epithelial permeability. Arch Ophthalmol 2003;121:1537-9.
15. Gekka M, Miyata K, Nagai Y, et al. Corneal epithelial barrier function in diabetic patients. Cornea 2004;23:35-7.
16. Yokoi N, Komuro A, Nishida K, et al. Effectiveness of hyaluronan on corneal epithelial barrier function in dry eye. Br J Ophthalmol 1997;81:533-6.
17. Yokoi N, Kinoshita S. Clinical evaluation of corneal epithelial barrier function with slit-lamp fluorophotometer. Cornea 1995;14:485-9.
18. Yokoi N, Kinoshita S, Akiyama K. A new slit-lamp fluorophotometer for the clinical evaluation of corneal epithelial barrier function. Acta Soc Ophthalmol Jpn 1994;98:641-7.
19. Shimazaki J, Fujishima H, Yagi Y, et al. Effects of diclofenac eye drops on corneal epithelial structure and function after small-incision cataract surgery. Ophthalmology 1996;103:50-7.
20. Shimazaki J, Shimmura S, Mochizuki K, et al. Morphology and barrier function of the corneal epithelium after penetrating keratoplasty: association with original diseases, tear function, and suture removal. Cornea 1999;18:559-04.
21. Göbbels M, Spitznas M, Oldendoerp J. Impairment of corneal epithelial barrier function in diabetics. Graefes Arch Clin Exp Ophthalmol 1989;227:142-4.
22. Alfonso EC, Rosa RH Jr. Fungal keratitis. In: Krachmer JH, Mannis MJ, Holland EJ, eds. Cornea. St Louis: Mosby, 1997:1253-65.
23. Hamada Y, Araki N, Koh N, et al. Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. Biochem Biophys Res Commun 1996;228:539-43.
24. Kawasaki Y, Fujii J, Miyazawa N, et al. Specific detections of the early process of the glycation reaction by fructose and glucose in diabetic rat lens. FEBS Lett 1998;441:116-20.
25. Suarez G, Rajaram R, Oronsky AL, et al. Nonenzymatic glycation of bovine serum albumin by fructose (fructation). Comparison with the Maillard reaction initiated by glucose. J Biol Chem 1989;264:3674-9.